Bobak R. Azamian Sells $906K of Tarsus Pharmaceuticals Inc (TARS) — SEC Form 4, Sep 09, 2026
Open-Market Net Sale · SEC Form 4
−$905,600
10b5-1 Plan
Equity position changed by -1.2%
Equity Position
861K sh
871,412 → 861,412
Equity Change
-1.2%
shares held after vs before
Filing Lag
2 business days
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Bobak R. Azamian CIK 0001827672 |
Director
CEO
|
Bobak R. Azamian at Tarsus Pharmaceuticals Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
$5,181,681
More from this insider at Tarsus Pharmaceuticals Inc
| 2026-09-03 | Sell | -$800,600 | View |
| 2026-06-22 | Sell | -$615,488 | View |
| 2026-03-19 | Sell | -$2,364,904 | View |
| 2026-03-17 | Exercise | — | View |
| 2026-03-09 | Award | — | View |
Non-Derivative Securities Transactions
| Title | Date | Type | Shares | Price | Net Total | Post-Txn | Ownership |
|---|---|---|---|---|---|---|---|
| Common StockF1F2F3 | 2026-09-04 | S - Sale 10b5-1 | 7,100 D | $90.27 | -$640,917 | 830,891 | Indirect By the Bobak Azamian Living Trust established April 16, 2018 |
| Common StockF1F4F3 | 2026-09-04 | S - Sale 10b5-1 | 2,900 D | $91.27 | -$264,683 | 827,991 | Indirect By the Bobak Azamian Living Trust established April 16, 2018 |
Non-Derivative Holdings
| Title | Shares Held | Ownership |
|---|---|---|
| Common Stock | 33,421 | Direct |
Footnotes (4)
- F1
- The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025. Show more
- F2
- The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $90.00 to $90.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Show more
- F3
- The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Show more
- F4
- The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $91.06 to $91.45. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Show more
Related filings at Tarsus Pharmaceuticals Inc
Institutional Holders
13F holders · Jun 30, 2026
256
institutional managers reporting a position
Largest by reported value
- Black Rock, Inc. $243M
- Deep Track Capital, Lp $231M
- Rtw Investments, Lp $211M
5%+ Holders · 13D/G
5 filers
-
Rtw Investments, Lp 8.1%
-
Black Rock, Inc. 7.4%
Other insiders at Tarsus Pharmaceuticals Inc
GET /v1/forms/4/0001827672-26-000013
API docs
View Original SEC Filing